Member of COVID R&D Alliance Report the First Patient Enrollment in COMMUNITY Study

 Member of COVID R&D Alliance Report the First Patient Enrollment in COMMUNITY Study

Member of COVID R&D Alliance Report the First Patient Enrollment in COMMUNITY Study

Shots:

  • Amgen, UCB, and Takeda reported that the first patient has been enrolled in the COMMUNITY trial. The study will test whether Amgen’s Otezla, Takeda’s lanadelumab, and UCB’s zilucoplan can reduce the severity of COVID-19 in hospitalized patients by moderating the immune system’s response to the disease
  • The focus of the trial is to identify an effective treatment for hospitalized COVID-19 patients, who are Grade 2 to Grade 5 on a clinical severity status 8-point ordinal scale. Trial sites are being established in hospitals across the globe to support enrollment in communities
  • This is the first time that the global pharmaceutical has come together to launch an adaptive clinical trial

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Stat

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post